Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis

Abstract

Transgenic mice expressing specific oncogenes usually develop tumors in a stochastic fashion suggesting that tumor progression is a multi-step process. To gain further understanding of the interactions between oncogenes and tumor suppressor genes during tumorigenesis, we have crossed a transgenic strain (TG.NK) carrying an activated c-neu oncogene driven by the MMTV enhancer/promoter with p53-deficient mice. c-neu transgenic mice have stochastic breast tumor formation and normal appearing salivary glands. However, c-neu mice heterozygous for a p53 deletion develop parotid gland tumors and loose their wild type p53 allele. c-neu mice with a homozygous p53 deletion have increased rates of parotid tumor onset suggesting that inactivation of p53 is required and sufficient for parotid gland transformation in the presence of activated c-neu. In contrast to the dramatic effect of p53 in parotid gland transformation, p53 loss has little effect on the rate or stochastic appearance of mammary tumors. In addition, p53 loss was accompanied by the down regulation of p21 in parotid gland tumors but not breast tumors. The parotid gland tumors were aneuploid and demonstrated increased levels of Cyclin D1 expression. These observations suggest that in c-neu transgenic mice, p53 alterations have differential tissue effects and may be influenced by the tissue specific expression of genes influencing p53 activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bargmann CI, Hung MC, Weinberg RA . 1986 Cell 45: 649–657

  • Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P . 1989 Cell 57: 931–936

  • Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ . 1995 Nature 377: 552–557

  • Califano J, Eisele DW . 1999 Otolaryngol. Clin. North Am. 32: 861–873

  • Cardiff RD, Sinn E, Muller W, Leder P . 1991 Am. J. Pathol. 139: 495–501

  • Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY . 1999 Oncogene 18: 7883–7899

  • Deng C, Zhang P, Harper JW, Elledge SJ, Leder P . 1995 Cell 82: 675–684

  • Donehower LA . 1997 Cancer Surv. 29: 329–352

  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A . 1992 Nature 356: 215–221

  • Earp HS, Dawson TL, Li X, Yu H . 1995 Breast Cancer Res. Treat. 35: 115–132

  • el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825

  • Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P . 1995 Oncogene 11: 181–190

  • Evans EP . 1987 In Monk, M. (ed.) Mammalian Development IRL Press Limited, Oxford pp. 93–114

  • Graus-Porta D, Beerli RR, Daly JM, Hynes NE . 1997 EMBO J. 16: 1647–1655

  • Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR . 1990 J. Pathol. 161: 195–200

  • Hand AR, Pathmanathan D, Field RB . 1999 Arch. Oral. Biol. 44: Suppl 1 S3–10

  • Harvey M, McArthur MJ, Montgomery Jr CA, Bradley A, Donehower LA . 1993 FASEB J. 7: 938–943

  • Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B . 1997 Mol. Cell. 1: 3–11

  • Hunter T . 1991 Cell 64: 249–270

  • Hynes NE . 1996 J. Mammary Gland Biol. Neoplasia 1: 199–206

  • Isola J, Chu L, DeVries S, Matsumura K, Chew K, Ljung BM, Waldman FM . 1999 Clin. Cancer Res. 5: 4140–4145

  • Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA . 1994 Curr. Biol. 4: 1–7

  • Jimenez RE, Wallis T, Tabasczka P, Visscher DW . 2000 Mod. Pathol. 13: 37–45

  • Kamio N . 1996 Virchows Arch. 428: 75–83

  • Knudson CM, Korsmeyer SJ . 1997 Nat. Genet. 16: 358–363

  • Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ . 1995 Science 270: 96–99

  • Lee JM, Bernstein A . 1993 Proc. Natl. Acad. Sci. USA 90: 5742–5746

  • Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines III GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG . 2000 Mol. Cell. Biol. 20: 672–683

  • Levine AJ . 1997 Cell 88: 323–331

  • Linke SP, Clarkin KC, Wahl GM . 1997 Cancer Res. 57: 1171–1179

  • Lucchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F, Vezzoni P, Clerici L . 1992 Cancer Lett. 64: 203–209

  • Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J, Strong LC . 1992 N. Engl. J. Med. 326: 1309–1315

  • Menard S, Tagliabue E, Campiglio M, Pupa SM . 2000 J. Cell. Physiol. 182: 150–162

  • Morgan SE, Kastan MB . 1997 Adv. Cancer Res. 71: 1–25

  • Muller S, Vigneswaran N, Gansler T, Gramlich T, DeRose PB, Cohen C . 1994 Mod. Pathol. 7: 628–632

  • Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P . 1988 Cell 54: 105–115

  • Oswald F, Lovec H, Moroy T, Lipp M . 1994 Oncogene 9: 2029–2036

  • Pignataro L, Capaccio P, Carboni N, Pruneri G, Ottaviani A, Buffa R, Broich G . 1998 Anticancer Res. 18: 1287–1290

  • Pinkas-Kramarski R, Alroy I, Yarden Y . 1997 J. Mammary Gland Biol. Neoplasia 2: 97–107

  • Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y . 1996 J. Biol. Chem. 271: 19029–19032

  • Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B . 1997 Nature 389: 300–305

  • Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG, El-Nagger AK . 1994 Cancer Res. 54: 5675–5682

  • Resnitzky D, Reed SI . 1995 Mol. Cell. Biol. 15: 3463–3469

  • Rice DH . 1999 Otolaryngol Clin. North Am. 32: 875–886

  • Samuelson LC . 1996 Annu. Rev. Physiol. 58: 209–229

  • Schulze A, Zerfass K, Spitkovsky D, Henglein B, Jansen-Durr P . 1994 Oncogene 9: 3475–3482

  • Sherr CJ . 1996 Science 274: 1672–1677

  • Shih C, Padhy LC, Murray M, Weinberg RA . 1981 Nature 290: 261–264

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . 1987 Science 235: 177–182

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MP . 1989 Science 244: 707–712

  • Stal O, Sullivan S, Sun XF, Wingren S, Nordenskjold B . 1994 Cytometry 16: 160–168

  • Tonin PN . 2000 Semin. Surg. Oncol. 18: 281–286

  • Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y . 1996 Mol. Cell. Biol. 16: 5276–5287

  • Varley JM, Evans DG, Birch JM . 1997 Br. J. Cancer 76: 1–14

  • Vogelstein B, Kinzler KW . 1992 Cell 70: 523–526

  • Webster MA, Muller WJ . 1994 Semin. Cancer Biol. 5: 69–76

  • Yin Y, Solomon G, Deng C, Barrett JC . 1999 Mol. Carcinog. 24: 15–24

Download references

Acknowledgements

We would like to thank D Shanmugarajah for technical assistance.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brodie, S., Xu, X., Li, C. et al. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis. Oncogene 20, 1445–1454 (2001). https://doi.org/10.1038/sj.onc.1204222

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204222

Keywords

This article is cited by

Search

Quick links